PARP Inhibitors for Breast and Ovarian Cancers
PARP inhibitors represent an exciting new class of anticancer agents and are currently being evaluating in phase III for a number of different indications.
Clinical Oncology in the 21st Century: Reflections on how Healthcare Providers Should Manage Their Public Personas on Social Media
It is important that clinicians engage with social media, since reputations are at risk by not knowing what is being said, shared, and discussed online about them online.
Could Healthcare Reform Speed Molecular Medicine Adoption?
Over the past decade drug development in cancer has shifted to an increasingly gene targetâ€“based approach.
Recognizing the Role of Bias in Patient Decision Making
Doctors are taught to think through medical decisions by listing a series of options, weighing the risks and benefits of each, and ultimately concluding on the superior option. This comparative maximization approach is drilled into us as medical students and residents.
Should Physicians Friend or Unfriend Social Media? 'It's Complicated'
Compared to other industries, the medical profession has been late in recognizing the many benefits of social media. In the past few years, it has entered into an uneasy relationship with the new medium.
Development of PI3K Inhibitors in Breast Cancer
The PI3K pathway is the most frequently altered pathway in cancer, and its activation has been shown to confer resistance to endocrine and HER2-targeted therapies preclinically.
Targeting Cell Cycle Progression: CDK4/6 Inhibition in Breast Cancer
Cyclin-dependent kinase (CDK) 4/6 inhibitors are novel agents that have shown promising results in the treatment of breast cancer.
Dr Phillips on the Treatment Landscape for Patients With MCL
Dr Chari on the Bridging the Gaps in Hematologic Malignancies Meeting
Dr Danilov on Addressing Unmet Needs in Hematologic Malignancies
Dr Saeed on the Use of Pola-R-CHP in Previously Untreated DLBCL
2 Commerce Drive Cranbury, NJ 08512